key: cord-1049688-10ucu0lt
authors: Liu, Ge; Carter, Brandon; Bricken, Trenton; Jain, Siddhartha; Viard, Mathias; Carrington, Mary; Gifford, David K.
title: Robust computational design and evaluation of peptide vaccines for cellular immunity with application to SARS-CoV-2
date: 2020-05-17
journal: bioRxiv
DOI: 10.1101/2020.05.16.088989
sha: 3438e9ea06fef6e6e8e6d77b679e2112db2c955c
doc_id: 1049688
cord_uid: 10ucu0lt

We present a combinatorial machine learning method to evaluate and optimize peptide vaccine formulations, and we find for SARS-CoV-2 that it provides superior predicted display of viral epitopes by MHC class I and MHC class II molecules over populations when compared to other candidate vaccines. Our method is robust to idiosyncratic errors in the prediction of MHC peptide display and considers target population HLA haplotype frequencies during optimization. To minimize clinical development time our methods validate vaccines with multiple peptide presentation algorithms to increase the probability that a vaccine will be effective. We optimize an objective function that is based on the presentation likelihood of a diverse set of vaccine peptides conditioned on a target population HLA haplotype distribution and expected epitope drift. We produce separate peptide formulations for MHC class I loci (HLA-A, HLA-B, and HLA-C) and class II loci (HLA-DP, HLA-DQ, and HLA-DR) to permit signal sequence based cell compartment targeting using nucleic acid based vaccine platforms. Our SARS-CoV-2 MHC class I vaccine formulations provide 93.21% predicted population coverage with at least five vaccine peptide-HLA hits on average in an individual (≥ 1 peptide 99.91%) with all vaccine peptides perfectly conserved across 4,690 geographically sampled SARS-CoV-2 genomes. Our MHC class II vaccine formulations provide 90.17% predicted coverage with at least five vaccine peptide-HLA hits on average in an individual with all peptides having observed mutation probability ≤ 0.001. We evaluate 29 previously published peptide vaccine designs with our evaluation tool with the requirement of having at least five vaccine peptide-HLA hits per individual, and they have a predicted maximum of 58.51% MHC class I coverage and 71.65% MHC class II coverage given haplotype based analysis. We provide an open source implementation of our design methods (OptiVax), vaccine evaluation tool (EvalVax), as well as the data used in our design efforts.

For each racial background, HLA class I and class II haplotypes were inferred using Hapferret [33] an implementation of the 129 Expectation-Maximization algorithm [34] . A total of 1200, 779, and 440 class I and 920, 537, and 502 class II haplotype 130 frequencies were derived in Black, White, and Asian populations, respectively. Computational models For a peptide vaccine to be effective, its constituent peptides need to be displayed, and thus a 133 computational vaccine design must be built upon a solid predictive foundation of what peptides will be displayed by each 134 MHC allele. Incorrect predictions could lead to failure of a pre-clinical or clinical trial at great human cost. To this end we are 135 concerned with the precision (true positives / all positives) of our predictions such that we maximize the chance that a peptide 136 predicted to be displayed will in fact be displayed. We are less concerned with our ability to recall all of the peptides that 137 will work as long as we have a set of suitable size that will work. We reduce the risk of false positives by employing multiple 138 computational methods to predict peptide-MHC binding. For design we use an ensemble of methods, and for evaluation we use 139 all methods separately. 140 For MHC class I design, we use an ensemble that outputs the mean predicted binding affinity of 141 and MHCflurry 1.6.0 [35, 19] . We find this ensemble increases the precision of binding affinity estimates over the individual 142 models on available SARS-CoV-2 experimental data (Table S1 ). For MHC class II design, we use . 143 For evaluation, we use our ensemble estimate of binding (MHC class I), as well as use binding predictions from a wide range PUFFIN [17] ) to ensure that all methods agree that we have a 146 good peptide vaccine. We validate these models on datasets containing experimentally-studied SARS-CoV-2 and SARS-CoV 147 peptides [38, 39, 40, 41] (see Section S1.2).

All models take as input a (MHC, peptide) pair and output predicted peptide-MHC binding affinity (IC50) on a nanomolar 149 scale. For both MHC class I and class II models, we consider peptides to be binders if the predicted MHC binding affinity 150 is ≤ 50nM [42] . This provides a conservative threshold to increase the probability of peptide display. Where our methods 151 require a probability of peptide-MHC binding (as in Equation 5), affinity predictions are capped at 50000nM and transformed 152 into [0, 1] using a logistic transformation, 1 − log 50000 (aff), where larger values correspond to greater likelihood of eliciting 153 an immunogenic response [42, 43, 44] . The ≤ 50nM binding affinity threshold corresponds to a threshold of ≥ 0.638 after 154 logistic transformation. We explored other criteria to classify peptides as binders and found using predicted binding affinity 155 with a 50nM threshold to meet these alternative criteria and maximize precision on available SARS-CoV-2 experimental data 156 (Table S1 ). 159 We eliminate peptides that are observed to mutate above an input threshold rate to improve coverage over all SARS-CoV-2 160 variants and reduce the chance that the virus will mutate and escape vaccine-induced immunity in the future. When possible, 161 we select peptides that are observed to be perfectly conserved across all observed SARS-CoV-2 viral genomes. Peptides that 162 are observed to be perfectly conserved in thousands of examples may be functionally constrained to evolve slowly or not at all.

If functional data are available, they can be used to supplement observed viral genome mutation rates by increasing mutation 164 rates over functionally non-constrained residues.

For SARS-CoV-2, we obtained the most up to date version of the GISAID database [29] (as of 2:02pm EST May 13, 2020, ac-166 knowledgements in Section S4) and used Nextstrain [30] (from GitHub commit 639c63f25e0bf30c900f8d3d937de4063d96f791) 167 to remove genomes with sequencing errors, translate the genome into proteins, and perform multiple sequence alignments 168 (MSAs). We retrieved 24468 sequences from GISAID, and 19288 remained after Nextstrain quality processing. After quality 169 processing, Nextstrain randomly sampled 34 genomes from every geographic region and month to produce a representative set 170 of 5142 genomes for evolutionary analysis. Nextstrain definition of a "region" can vary from a city (e.g., "Shanghai") to a 171 larger geographical district. Spatial and temporal sampling in Nextstrain is designed to provide a representative sampling of 172 sequences around the world.

The 5142 genomes sampled by Nextstrain were then translated into protein sequences and aligned. We eliminated viral 174 genome sequences that had a stop codon, a gap, an unknown amino acid (because of an uncalled nucleotide in the codon), or 175 had a gene that lacked a starting methionine, except for ORF1b which does not begin with a methionine. This left a total of 176 4690 sequences that were used to compute peptide level mutation probabilities. For each peptide, the probability of mutation 177 was computed as the number of non-reference peptide sequences observed divided by the total number of peptide sequences 178 observed. for class I or endosomes for class II. Any peptide that spans any of these cleavage sites is removed from consideration. This 184 removes 3,739 peptides out of the 154,996 we consider across windows 8-10 (class I) and 13-25 (class II) (∼2.4%). 186 We eliminate all peptides that are predicted to have N-linked glycosylation as it inhibits both MHC loading and T cell recognition 187 of peptides [46] . Glycosylation is a post-translational modification that involves the covalent attachment of carbohydrates to 188 specific motifs on the surface of the protein. We identified peptides that may be glycosylated with the NetNGlyc N-glycosylation 189 prediction server [47] . We verified these predictions for the Spike protein using experimental data of Spike N-glycosylation 190 from Cryo-EM and tandem mass spectrometry [48, 49] . A majority of the potential N-glycosylation sites (16 out of 22) were 191 identified in both experimental studies, and further supported by homologous regions with glycosylation in SARS-CoV [50] . 192 We found that that for the Spike protein when NetNGlyc predicted a non-zero probability of a site being N-glycosylated it 193 was experimentally identified as a real or likely N-glycosylation site. Therefore, we eliminated all peptides where NetNGlyc 194 predicted a non-zero N-glycosylation probability in any residue. This resulted in the elimination of 18,957 of the 154,996 195 peptides considered (∼12%). 

T cells are selected to ignore peptides derived from the normal human proteome, and thus we remove any self peptides from 198 consideration for a vaccine. In addition, it is possible that a vaccine might stimulate the adaptive immune system to react 199 to a self peptide that was presented at an abnormally high level, which could lead to an autoimmune disorder. All peptides 200 from SARS-CoV-2 were scanned against the entire human proteome downloaded from UniProt [31] under Proteome ID 201 UP000005640. A total of 48 exact peptide matches (46 8-mers, two 9-mers) were discovered and eliminated from consideration. EvalVax-Unlinked considers MHC allele frequencies at each HLA locus independently, and computes the likelihood that at 213 least one peptide from a vaccine set is displayed at any locus. Both methods take into consideration MHC allele frequency, 214 allelic zygosity, and for EvalVax-Robust, linkage disequilibrium (LD) among loci. We also take glycosylation and cleavage 215 sites into consideration when evaluating vaccines by setting binding affinity to zero for peptides with non-zero glycosylation 216 probability or on cleavage sites. thus EvalVax-Robust computes the probability of having at least N predicted peptide-HLA binding hits for each individual in 222 the population.

Assuming for each of the HLA-A,B,C loci there are M A , M B , M C alleles respectively, for a given haploid A i B j C k , the 224 haplotype frequency is defined as G(i, j, k) and ∑

k=0 G(i, j, k) = 1. We assume independence of inherited haplotypes 225 and compute the frequency of a diploid genotype as:

For each allele A, e(A) denotes the number of peptides predicted to bind to the allele with ≤ 50nM affinity, which we call the 227 number of peptide-HLA hits. Then for each possible diploid genotype we compute the total number of peptide-HLA hits of the 228 genotype as the sum of e(A) of the unique alleles in the genotype (there can be 3-6 unique alleles depending on the zygosity of 229 each locus):

We then compute the frequency of having exactly k peptide-HLA hits in the population as:

We define the population coverage objective function for EvalVax-Robust as the probability of having at least N peptide-HLA 232 hits in the population, where the cutoff N is set to the minimum number of displayed vaccine peptides desired:

When we evaluate metrics on a world population, we equally weight population coverage estimations over three population When haplotype frequencies are not available for a population, we can evaluate a vaccine using MHC allele frequencies that 239 assume independence and compute the probability that at least one peptide binds to any of the alleles at any of the loci. To 240 encourage a diverse set of peptides to bind to a single MHC allele, we use the predicted binding probability of a peptide to an 241 allele instead of using a binary indicator of binding. This permits multiple peptides to contribute to the probability score at each 242 allele. Considering K loci {L 1 , ..., L K }, for each locus there are M k alleles A 1 , ..., A M k and the allele frequency is defined as

Given a set of N peptides {P n=1:N }, for each allele (of locus L k ) the predicted binding probability 244 to peptide P n is e n k (A i ). Assuming no competition between peptides, the probability that allele A i ends up having at least one 245 peptide bound is:

We define the diploid frequency of alleles as

, and we conservatively assume that a homozygous 247 diploid locus does not improve the chance of peptide presentation over a single copy of the locus. Thus, the probability that a 248 diploid genotype has at least one peptide bound is defined as:

Therefore, the probability that a person in the given population displays at least one peptide in the set {P n } at a particular locus 250 L k is calculated by:

To combine different loci assuming no linkage disequilibrium, the probability that a person in the given population has at least 252 one locus that binds to at least one peptide from {P n } is defined as:

which is the evaluation metric for EvalVax-Unlinked. 254 We conservatively only consider peptides with predicted binding affinity ≤ 50nM. We set values of e n k (A i ) weaker than 255 50nM predicted binding affinity to zero. This constraint on peptide binding is in addition to all of the other peptide filters in 256 Section 2.3. When we evaluate on a world population, we equally weight population coverage estimates over 15 geographic 257 regions (see Results for list of regions) as the final objective function. 259 We use beam search over a set of candidate peptides to efficiently search for an optimal subset of peptides that maximizes a 260 desired EvalVax-Unlinked or EvalVal-Robust based objective function. Our beam search procedure is parallelizable across CPU 261 cores, and we typically use from 40 to 96 cores. We use a beam size of k = 10 for MHC class I and k = 5 for MHC class II. 287 We validate our computational models on datasets containing experimentally-studied SARS-CoV-2 and SARS-CoV peptides [38, 288 39, 40, 41] (details in Section S1.2). We find classifying peptides as binders by predicted binding affinity ≤ 50nM maximizes 289 AUROC and precision in classification of stable binders over alternative predictors and binding criteria (Table S1 ). Our Figure S1 . We observed that it is more difficult to optimize vaccines with S, N, and M proteins only. We expect this is 321 because we have fewer candidate peptides to cover all of our haplotype combinations.

We limited our candidates to peptides with length 8-10 and zero predicted probability of glycosylation.

We also excluded peptides that have been observed with any mutation. We use the mean predicted binding affinity values from Asian populations, percentage of peptides that are predicted to be glycosylated, peptides observed to mutate with greater than However, many fail to show a high probability of higher hit counts, indicating a lack of predicted redundancy if a single peptide 355 is not displayed. We also evaluate randomly selected peptide sets of size 19 from predicted binders of MHC class I and II, 356 where a binder is defined as a peptide that is predicted to bind with ≤ 50nM to more than 5 of the alleles in the MHC class. We 357 found that a random binder set can achieve coverage that outperforms some of the proposed vaccines that we use as baselines.

358 Table 1 summarizes EvalVax results for all baselines with a vaccine peptide count less than 150 peptides. We also included 359 evaluation on peptide sets derived from taking all sliding windows with proper size for MHC class I and II from the S protein or 360 S1 subunit, and evaluated an average of 500 random designs for MHC class I or class II that are comprised of 19 peptides that 361 are predicted to bind either MHC class I and II. We found that the baseline methods all provide less coverage than OptiVax 362 derived sets, and some contain peptides predicted to be glycosylated or have a high observed mutation probability (Table 1) . 363 We also observe some baselines contain peptides that sit on the cleavage sites or overlap with self-peptides. In addition, we 364 found that for class II MHC coverage the S protein alone is unable to achieve more than 88% coverage for n ≥ 0 and 75.9% 365 coverage n ≥ 5. 367 We evaluated all Table 1 vaccine designs using eleven independent peptide-MHC binding prediction methods to ensure 368 that the performance observed in Table 1 is not an artifact. For MHC class I prediction we validated using seven methods: 3 0.00% 0.00% 0.00% 0.00% 0.00% 0.000 0.000 0.000 66.67% 100.00% 0.00% S1 0.00% Table 1 . Comparison of existing baselines, S-protein peptides, and OptiVax designed peptide vaccines (using full set of proteins or S/M/N proteins only) on various population coverage evaluation metrics and vaccine quality metrics (percentage of peptides with larger than 0.1% probability of mutating or with non-zero probability of being glycosylated). The list is sorted by EvalVax-Robust p(n ≥ 1). Random subsets are generated 200 times.The binders used for generating random subsets are defined as peptides that is predicted to bind with ≤ 50nM to more than 5 of the alleles.

potential cytotoxic T cell epitopes. The Journal of Immunology, 153(12):5586-5592, 1994. 

We evaluate peptide-MHC binding predictions on a set of experimentally assessed SARS-CoV-2 peptides whose peptide-MHC (Table S1 ). AUROC and average precision are computed using raw predictions, and 621 the remaining metrics are computed using binarized predictions based on the respective binding criteria (using scikit-learn [71]).

We compare classification performance using different binding criteria (see Section S1.1) and find in general that classifying 623 binders using predicted binding affinity using a 50nM threshold maximizes AUROC and precision (Table S1 ). We find that our 624 mean ensemble of NetMHCpan-4.0 and MHCflurry further improves classification AUROC and precision over the individual 625 models for predicting MHC class I epitopes. On MHC class II data, we note NetMHCIIpan-4.0 achieves AUROC 0.848 and 626 precision 0.625 using a 500nM threshold (Table S1 ). While NetMHCIIpan-4.0 with a 50nM threshold does not identify any 627 peptides in this dataset as binders, we use this stricter threshold in our vaccine designs as it is more conservative and less likely 628 to admit false positive binders. In general, we find performance of PUFFIN with a 50nM binding threshold comparable to 629 alternative methods on both MHC class I and class II data and use PUFFIN as part of our vaccine design evaluation. 630 We additionally validate our computational models using previously reported SARS-CoV T cell epitopes from experimental protein. Table S2 shows the performance of our peptide-MHC binding prediction models on these SARS-CoV peptides. 

See supplementary table in Supplementary_S3_evaluation_on_different_tools.xlsx. 638 S4 Detailed GISAID accessions

GISAID_Acknowledgements.xlsx for acknowledgements